Jaguar Health (JAGX) Stock Climbs Over 34% After-Hours: What's Going On?

Jaguar Health Inc. (NASDAQ:JAGX) shares soared 34.67% to $6.37 in after-hours trading on Monday. In the regular session, JAGX closed at $4.73, up 29.23%, according to Benzinga Pro data. On Monday, the stock of the California-based commercial-stage pharmaceuticals company experienced an elevated trading session. Volume reached 21.90 million shares, about 7.3 times its average of 3.01 million. Special Dividend Details The board declared one share of Series R Convertible Preferred Stock for each common share outstanding. Holders of record on Oct. 13 will qualify, with payment expected Oct. 15, the filing said. The ex-dividend date will be announced once Nasdaq determines the date. Each Series R share will automatically convert into five common shares on Nov. 2. Conversions are capped at 11.625 million common shares and a 19.99% ownership limit per holder. The preferred shares carry no dividends or voting rights and will not be listed. Read Also: Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety Debt Payments Pushed to 2027 The company also amended royalty agreements with Uptown Capital and Streeterville Capital. Monthly payments now begin Jan. 1, 2027, instead of Oct. 1, 2026, and will be the greater of $750,000 or the actual royalty amount owed. The maturity of the The maturity of the $6.22 million Streeterville note was also extended to Jan. 1, 2027. Trading Metrics, Technical Analysis Jaguar Health has a market capitalization of about $9.20 million. The company has approximately 1.95 million shares outstanding. JAGX has a Relative Strength Index (RSI) of 45.39. Over the past 12 months, the stock has fallen 99.59%. Currently, JAGX is trading very close to its yearly low. .benzinga-widget#bz-embed-widget-block_279195895da41ae52d3fbd1c4917efb8 iframe.w-full { width: 100%; } @media (max-width: 600px) { .benzinga-widget#bz-embed-widget-block_279195895da41ae52d3fbd1c4917efb8 iframe.w-full { height: 670px; } } See More: Top Value Stocks Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Photo Courtesy: Arsenii Palivoda on Shutterstock.com